The independent source for health policy research, polling, and news.
1,401-1,420 of 3,998 results
Aggressive sales tactics have allegedly led surgeons to use defective or wrong-size implants, screws or other products on patients, including former Olympian Mary Lou Retton.
Facing bankruptcy, Detroit largely dismantled its public health department in 2012, and the city essentially went two years without a government-run public health system. Five years later, this major American city offers a grim cautionary tale.
Providence, the country’s 10th-biggest hospital chain, says it’s too expensive to upgrade an older hospital, so it will join forces with giant Kaiser Permanente to build a new one.
Community Health Systems, a large, for profit hospital chain, shrank from more than 200 to 84 facilities. It is continuing to sue patients for hospitals that now exist as little more than legal entities.
Big Bend Regional Medical Center, the only hospital in a sparsely populated region of West Texas, announced that because of a nursing shortage its labor and delivery unit must close for days at a time and patients must go instead to a hospital an hour away.
The Biden administration is weighing how to treat urgent care clinics as part of broad regulations banning surprise, out-of-network medical bills. At the heart of the matter: What counts as an emergency?
California Gov. Gavin Newsom faces a recall election in September, fueled in part by anger over his pandemic policies. The health care industry has ponied up more than $4.8 million so far to defend the first-term Democrat.
Health plans’ coverage of the medication, branded as Wegovy — which has a $1,300-a-month price tag — is not a sure thing.
Pharmaceutical companies routinely cover the cost of patient copays for expensive drugs under private insurance. A federal judge could make the practice legal for millions on Medicare as well.
In a suburb of Denver, a doctor runs a clinic that finds creative solutions to treat a large refugee and immigrant population, sometimes to the dismay of the medical establishment.
Patients seem to like remote visits, and health care providers now depend on them. But outages, freezing and other glitches cost time and money, and compromise quality of care.
The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.
A year and a half after Sutter Health agreed to a tentative settlement in a closely watched antitrust case, the San Francisco judge presiding over the case indicated she would sign off on the terms, pending agreement on another contentious issue: attorney fees.
With covid cases on the upswing again around the country, partisan division remains over how to address the pandemic. Meanwhile, the Biden administration proposes bigger penalties for hospitals that fail to make their prices public as required. Stephanie Armour of The Wall Street Journal, Alice Miranda Ollstein of Politico and Tami Luhby of CNN join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite stories of the week they think you should read, too.
The July 9 directive addresses the importation of prescription drugs and broader efforts to reduce the high cost of medicines.
Only severely injured patients are supposed to be billed for “trauma team alert” fees that can exceed $50,000.
When patients with common terminal illnesses such as cancer seek permission for compassionate use of therapies in the testing stage, their requests often are approved. But those with more unusual illnesses say drug companies are rarely willing to provide access.
A group of New York senior living facilities offer teens from 10 underserved schools the chance to volunteer and get free training for entry-level health jobs, career coaching and assistance on college prep.
The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.
Your dutiful columnist tried to make use of a federal “transparency” rule to compare the prices of common medical procedures in two California health care systems. It was a futile exercise.
© 2026 KFF